论文部分内容阅读
目的观察罗格列酮对糖基化终产物(AGEs)干预的人肾小球系膜细胞(HRMC)β1-整合素表达以及细胞外基质(ECM)成分Ⅳ型胶原分泌的影响。方法用葡萄糖和牛血清白蛋白制备糖基化终产物(AGE-BSA),用不同浓度的罗格列酮(1.0、10.0、100.0μmol/L)和AGE-BSA共同干预以及AGE-BSA单独干预(AGEs组)HRMC。RT-PCR法测定细胞β1-整合素mRNA水平;Western blot法检测β1-整合素蛋白表达;放射免疫分析法测定细胞培养上清液Ⅳ型胶原含量。结果与AGEs组相比,各浓度罗格列酮均能下调由AGE-BSA诱导的HRMCβ1-整合素mRNA和蛋白表达的升高,并抑制培养上清液Ⅳ型胶原的分泌(P<0.05)。结论罗格列酮可能通过抑制AGEs引起的HRMCβ1-整合素mRNA和蛋白表达及Ⅳ型胶原含量的升高,发挥一定的肾脏保护作用。
Objective To observe the effects of rosiglitazone on the expression of β1-integrin in human glomerular mesangial cells (HRMC) and the secretion of extracellular matrix (ECM) type Ⅳ collagen by advanced glycation end products (AGEs). Methods The advanced glycation end products (AGE-BSA) were prepared by glucose and bovine serum albumin. The cells were treated with different concentrations of rosiglitazone (1.0, 10.0 and 100.0 μmol / L) and AGE-BSA and AGE- AGEs group) HRMC. Β1-integrin mRNA was detected by RT-PCR, β1-integrin protein was detected by Western blot, and collagen Ⅳ was detected by radioimmunoassay. Results Compared with AGEs group, rosiglitazone at various concentrations could downregulate the mRNA and protein expression of HRMCβ1-integrin induced by AGE-BSA and inhibit the secretion of type Ⅳ collagen in culture supernatant (P <0.05) . Conclusion Rosiglitazone may exert certain renal protective effects by inhibiting the expression of HRMCβ1-integrin mRNA and protein and the increase of collagen type Ⅳ induced by AGEs.